| Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma … V Vilgrain, H Pereira, E Assenat, B Guiu, AD Ilonca, GP Pageaux, A Sibert, ... The Lancet Oncology 18 (12), 1624-1636, 2017 | 819 | 2017 |
| Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study F Carrat, H Fontaine, C Dorival, M Simony, C Hezode, V De Ledinghen, ... The Lancet 393 (10179), 1453-1464, 2019 | 578 | 2019 |
| Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7. 5 cells V Ramakrishnaiah, C Thumann, I Fofana, F Habersetzer, Q Pan, ... Proceedings of the National Academy of Sciences 110 (32), 13109-13113, 2013 | 560 | 2013 |
| A placebo-controlled trial of bezafibrate in primary biliary cholangitis C Corpechot, O Chazouillères, A Rousseau, A Le Gruyer, F Habersetzer, ... New England Journal of Medicine 378 (23), 2171-2181, 2018 | 524 | 2018 |
| Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials SA Harrison, VWS Wong, T Okanoue, N Bzowej, R Vuppalanchi, ... Journal of hepatology 73 (1), 26-39, 2020 | 383 | 2020 |
| Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a … M Bourlière, JP Bronowicki, V De Ledinghen, C Hézode, F Zoulim, ... The Lancet Infectious Diseases 15 (4), 397-404, 2015 | 373 | 2015 |
| In vivo tropism of hepatitis C virus genomic sequences in hematopoietic cells: influence of viral load, viral genotype, and cell phenotype H Lerat, S Rumin, F Habersetzer, F Berby, MA Trabaud, C Trépo, ... Blood, The Journal of the American Society of Hematology 91 (10), 3841-3849, 1998 | 337 | 1998 |
| Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation X Forns, M Charlton, J Denning, JG McHutchison, WT Symonds, ... Hepatology 61 (5), 1485-1494, 2015 | 257 | 2015 |
| HCV-induced epigenetic changes associated with liver cancer risk persist after sustained virologic response N Hamdane, F Jühling, E Crouchet, H El Saghire, C Thumann, MA Oudot, ... Gastroenterology 156 (8), 2313-2329. e7, 2019 | 232 | 2019 |
| Diagnostic accuracy of the Multistix 8 SG reagent strip in diagnosis of spontaneous bacterial peritonitis JB Nousbaum, JF Cadranel, P Nahon, EN Khac, R Moreau, T Thévenot, ... Hepatology 45 (5), 1275-1281, 2007 | 213 | 2007 |
| A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses ER Verrier, CC Colpitts, C Bach, L Heydmann, A Weiss, M Renaud, ... Hepatology 63 (1), 35-48, 2016 | 205 | 2016 |
| Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos (t) ide-naive patients with chronic hepatitis B AS Lok, H Trinh, G Carosi, US Akarca, A Gadano, F Habersetzer, ... Gastroenterology 143 (3), 619-628. e1, 2012 | 191 | 2012 |
| Analysis of hepatitis B virus genotypes and pre‐core region variability during interferon treatment of HBe antigen negative chronic hepatitis B X Zhang, F Zoulim, F Habersetzer, S Xiong, C Trépo Journal of medical virology 48 (1), 8-16, 1996 | 188 | 1996 |
| Fulminant hepatitis with severe lactate acidosis in HIV‐infected patients on didanosine therapy F Bissuel, F Bruneel, F Habersetzer, D Chassard, L Cotte, M Chevallier, ... Journal of internal medicine 235 (4), 367-372, 1994 | 178 | 1994 |
| Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients S Pol, M Bourliere, S Lucier, C Hezode, C Dorival, D Larrey, ... Journal of hepatology 66 (1), 39-47, 2017 | 149 | 2017 |
| Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents F Xiao, I Fofana, L Heydmann, H Barth, E Soulier, F Habersetzer, ... PLoS pathogens 10 (5), e1004128, 2014 | 141 | 2014 |
| Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta D Roulot, S Brichler, R Layese, Z BenAbdesselam, F Zoulim, V Thibault, ... Journal of Hepatology 73 (5), 1046-1062, 2020 | 135 | 2020 |
| Liver‐related deaths in HIV‐infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 study in collaboration with the Mortalite … E Rosenthal, D Salmon‐Ceron, C Lewden, V Bouteloup, G Pialoux, ... HIV medicine 10 (5), 282-289, 2009 | 133 | 2009 |
| Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb … M Moehler, J Heo, HC Lee, WY Tak, Y Chao, SW Paik, HJ Yim, KS Byun, ... Oncoimmunology, 2019 | 116 | 2019 |
| A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C F Habersetzer, G Honnet, C Bain, M Maynard–Muet, V Leroy, JP Zarski, ... Gastroenterology 141 (3), 890-899. e4, 2011 | 114 | 2011 |
